|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic |
Yair Lotan, MD and Daniel Parker, MD
Yair Lotan and Daniel Parker join Ashish Kamat in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotan offers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. |
|
|
|
|
|
|
|
|
|
|
| Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT |
Siamak Daneshmand, MD and Marek Babjuk, MD, Ph.D.
Siamak Daneshmand and Marek Babjuk join Ashish Kamat in this conversation on improving tumor detection through improved visibility and reducing recurrence rates of bladder cancer. |
|
|
|
|
|
|
|
|
|
|
| Realities of Bladder Cancer In Women |
| Sima Porten, MD, MPH, Anne K. Schuckman, MD, Kristen R. Scarpato, MD, MPH, and Svetlana Avulova, MD |
| Kristen Scarpato, Svetlana Avulova, and Anne Schuckman join Sima Porten in this conversation on the realities of diagnosis and treatment of bladder cancer in women. They start by evaluating a patient case to highlight some women who present with bladder cancer and discuss what's most important when we talk about caring for these patients and how to improve care. |
|
|
|
|
|
|
|
|
|
|
|
|
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC
|
|
Richard S. Matulewicz, MD, MS
|
| Richard Matulewicz joins Ashish Kamat in presenting findings on the association of smoking status on the recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy.
|
|
|
|
|
|
|
|
|
|
|
|
| The Impact of Blue Light Cystoscopy Use Among Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence by Race
|
| Stephen B. Williams, MD, MS, FACS
|
| Bladder Cancer is the 6th most common type of cancer in the United States and is estimated that there will be 81,180 new cases with approximately 17,100 dying of this disease in 2022. Of newly diagnosed bladder cancer cases, approximately 75% are non-muscle-invasive bladder cancer (NMIBC). Racial disparities have been previously described with Blacks noted to have worse bladder cancer-specific survival and are associated with up to a 2-fold increase of bladder cancer-specific death when compared to Whites.
|
|
|
|
|
|
| Reduction of Residual Tumors by Photodynamic Diagnosis-Assisted TURBT Using 5-Aminolevulinic Acid for High-Risk Nonmuscle-Invasive Bladder Cancer (BRIGHT Study)
|
| Taketo Kawai, MD |
| Taketo Kawai presents an analysis assessing the role of photodynamic diagnosis-assisted TURBT (PDD-TURBT) to reduce the residual tumor in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). High-risk NMIBC has a high rate of residual tumor following TURBT (40-60%). Thus, many guideline bodies recommend a second re-TUR. |
|
|
|
|
|
|
|
|
|
|
Combined miRNA and SERS Urine Liquid Biopsy for the Point-of-Care Diagnosis and Molecular Stratification of Bladder Cancer - Beyond the Abstract
|
| Mihnea P. Dragomir, MD, Ph.D., Vlad Moisoiu, MD, Ph.D., and Tudor Moisoiu, MD, Ph.D. |
| It is no news that one class of molecules alone cannot reach the accuracy required for the clinical implementation of screening by liquid biopsy. Therefore, we combined, for the first time, microRNA profiling and surface-enhanced Raman spectroscopy (SERS) for the diagnosis of bladder cancer on urine samples. In order to mimic a real-life clinical setting, we used a portable Raman spectroscope for the SERS profiling of urine and selected a panel consisting of only three microRNAs that can be measured quickly using quantitative PCR. |
|
|
|
|
|
| Photodynamic Detection and Photodynamic Therapy in Bladder Cancer |
| Stephen B. Williams, MD, MS, FACS |
| This study from an equal access setting in the VA observed a significantly decreased risk of recurrence and prolonged time interval to recurrence following BLC compared to the pre-study WLC. There was no difference in any bladder cancer outcomes by race. BLC use results in decreased rates of recurrence and longer time intervals to recurrence with current research underway to understand biological and treatment implications. |
|
|
|
|
|
| Conservative Management of Urothelial Cancer: How to Improve the Diagnosis Assessment |
| Alberto Breda, MD |
| Alberto Breda presents on how to improve the diagnosis assessment for patients with upper tract urothelial carcinoma. Achieving a correct diagnosis is crucial to assess the patient’s risk. Ureteroscopy remains decisive in determining treatment of upper tract urothelial carcinoma. The merger of new technologies and urinary biomarkers are helping the urologist to break through the limits of the standard techniques. |
|
|
|
|
|
|
|
|
|
|
|
